Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, ...

Quest Diagnostics DGX is well-poised to grow in the coming quarters owing to its investments in advanced diagnostics to deliver and scale innovative services. The company’s growth strategy includes ...

By using a mobile app and patient portal called MyQuest, “adult users can prompt the tool to define test names and medical terminology from their results reports, as well as translate the meaning of ...

Quest Diagnostics (NYSE:DGX) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Quest Diagnostics (NASDAQ:DGX) posted better-than-expected earnings for the third quarter on Tuesday. While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the ...

In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

What To Know: While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP earnings per share guidance to a range of $8.58 to $8.66 from a ...